Evidence & methodology

How the Virtual Clinic Works

A deterministic teaching simulator designed to make clinical reasoning visible, reproducible, and reviewable.

What is modeled

Procedural virtual patients

Each GEN-* case is generated locally from a stable seed. Age, refraction, axial length, longitudinal change, treatment, adherence, tolerance, measurement availability, candidacy, family response, and follow-up are generated as one connected case.

The same seed always produces the same patient. Runtime generation does not call AI services, remote clinical APIs, or token-consuming systems.

Internal consistency

One visible case, one truth model

Generator audits check thousands of cases for contradictions between visible facts, required tests, treatment candidacy, acceptable plans, family response, and follow-up. Scoring audits verify that answer-key visits are not penalized.

When longitudinal records are unavailable, progression is explicitly treated as not yet measurable. Current age, refraction, and visible risk factors may still support an initial treatment discussion.

Evidence governance

Evidence by clinical assertion

Use this index to see what each major teaching assertion is based on, what the evidence can support, and where the app deliberately limits its interpretation. Source links open the paper or report in a new tab.

Foundations

Most childhood myopia-control evidence applies to typical juvenile-onset myopia caused mainly by axial elongation.

What it supports. IMI separates terms that describe when myopia begins from terms that describe its cause. Most treatment trials measure both cycloplegic refraction and axial length.

Limits. Juvenile-onset describes timing; axial describes the cause; high myopia describes the amount. Do not automatically apply these trial results to myopia caused mainly by the cornea, lens, syndrome, disease, or medication.

SourcesIMI Defining and Classifying Myopia (2019) ↗Consensus evidence reportBullimore and Brennan. Juvenile-Onset Myopia—Who to Treat and How to Evaluate Success (2023) ↗Clinical evidence reviewIMI Myopia Correction, Control and Management: Recommended Usage (2025) ↗Consensus terminology report

Foundations

Each additional diopter of myopia is associated with clinically meaningful increases in the risk of myopic maculopathy, retinal detachment, posterior subcapsular cataract, and open-angle glaucoma.

What it supports. A 2021 synthesis estimated per-diopter relative risk increases of 58% for myopic maculopathy, 30% for retinal detachment, 21% for posterior subcapsular cataract, and 20% for open-angle glaucoma. A five-study model estimated that 1 D less final myopia could reduce myopic-maculopathy likelihood by about 40%.

Limits. These are population associations and model estimates—not the absolute risk for one patient or direct treatment-trial results. Estimates vary with age, population, refraction, axial length, and how each outcome was defined.

SourcesIMI Impact of Myopia (2021) ↗Consensus evidence reportBullimore and Brennan. Myopia Control: Why Each Diopter Matters (2019) ↗Population risk modelBullimore et al. The Risks and Benefits of Myopia Control (2021) ↗Evidence synthesis and risk modelHaarman et al. The Complications of Myopia (2020) ↗Systematic review and meta-analysis

Risk assessment

Age, refraction, parental myopia, education, near work, and outdoor time are linked with myopia onset. Outdoor time is the clearest factor that can be changed.

What it supports. The IMI review summarizes genetic and environmental evidence. In CLEERE, cycloplegic spherical equivalent predicted onset better than the other clinical factors tested.

Limits. Education and near work are associated with myopia, but neither provides a simple single cause. Evidence that a specific device causes myopia is weaker than the evidence supporting outdoor time.

SourcesIMI Risk Factors for Myopia (2021) ↗Consensus evidence reportZadnik et al. Prediction of Juvenile-Onset Myopia (2015) ↗Longitudinal cohort

Risk assessment

Low hyperopic reserve for age is a useful warning sign for juvenile myopia onset.

What it supports. The CLEERE cohort found baseline cycloplegic spherical equivalent to be the strongest single predictor among the factors evaluated and reported age-specific risk cut points.

Limits. These cutoffs mark higher risk in a group. They are not a diagnosis or an automatic reason to start optical treatment. Consider how refraction was measured and the rest of the clinical picture.

SourcesZadnik et al. Prediction of Juvenile-Onset Myopia (2015) ↗Longitudinal cohort

Prevention

Outdoor time has the best evidence for delaying myopia onset. Drug treatment before onset has only been studied in specific groups and dosing schedules.

What it supports. Risk-factor and prevention reviews support outdoor exposure for onset prevention. LAMP2 enrolled nonmyopic children aged 4 to 9 with cycloplegic SER +1.00 to 0.00 D. Two-year myopia incidence was 28.4% with nightly 0.05% atropine, 45.9% with 0.01%, and 53.0% with placebo; 0.01% did not significantly differ from placebo.

Limits. Outdoor time does not reliably slow myopia after onset. LAMP2 does not prove that atropine prevents myopia permanently or that its results apply to every concentration or population.

SourcesIMI Risk Factors for Myopia (2021) ↗Consensus evidence reportYam et al. LAMP2 Randomized Clinical Trial (2023) ↗Randomized clinical trial

Risk assessment

Age helps frame the likelihood of continued progression, but does not determine an individual child's future course.

What it supports. Eleven years of COMET follow-up show that stabilization becomes more common through later adolescence and varies across the studied population.

Limits. COMET reports group patterns. Its age curves—and one quiet interval—cannot predict when one child will stop progressing.

SourcesCOMET Group. Myopia Stabilization and Associated Factors (2013) ↗Longitudinal cohort

Progression measurement

The same axial elongation rate can be normal at one age and concerning at another.

What it supports. A 2024 systematic review found that untreated younger myopic children usually have faster axial elongation. Average growth also differed between the broad race groups studied.

Limits. These are group averages with wide ranges. Use them as a comparison, not as an exact expected growth rate or treatment-effect percentage for one child.

SourcesBrennan et al. Influence of Age and Race on Axial Elongation (2024) ↗Systematic review and meta-regression

Progression measurement

Expected untreated refractive progression slows with age and differs between the broad population groups in the compiled reference table.

What it supports. The Nixon and Brennan clinical guide provides age-specific untreated mean SER progression from ages 6 through 18 for East Asian and non-East Asian myopic children.

Limits. The table is a compiled clinical reference and does not provide prediction intervals. Use it to compare age patterns, not to predict one child's exact untreated progression or treatment effect.

SourcesNixon and Brennan. Managing Myopia: A Clinical Response to the Growing Epidemic (2020) ↗Compiled clinical reference

Progression measurement

Repeated axial-length measurements show eye growth directly and are essential for monitoring orthokeratology, which changes corneal refraction.

What it supports. IMI instrumentation guidance treats refraction and axial length as complementary core measures, emphasizes noncontact biometry, and recommends consistent techniques for longitudinal interpretation.

Limits. Not every clinic has a biometer. One measurement shows eye size, not growth. Age-based charts help with interpretation but cannot label one child as a responder or nonresponder.

SourcesIMI Instrumentation for Myopia Management (2025) ↗Consensus evidence reportIMI Clinical Myopia Control Trials and Instrumentation (2019) ↗Consensus evidence report

Progression measurement

Cycloplegic refraction is the reference standard for classifying pediatric refractive error and for comparable refractive progression outcomes.

What it supports. The 2025 IMI instrumentation report recommends cycloplegia in the clinical workup through age 20 and identifies cycloplegic subjective refraction as the gold standard, with cycloplegic retinoscopy and autorefraction as alternatives.

Limits. Cycloplegia is not needed at every fit or safety check. Use it when the visit is meant to establish the diagnosis or compare refractive change.

SourcesIMI Instrumentation for Myopia Management (2025) ↗Consensus evidence report

Treatment selection

Provide appropriate full correction rather than intentional under-correction or over-minusing as a myopia-control strategy.

What it supports. IMI clinical guidance recommends full-time myopic correction and reports no myopia-control benefit from intentional under-correction.

Limits. The exact correction and wear plan still depends on current refraction, visual function, symptoms, and the selected treatment modality.

SourcesIMI Clinical Management Guidelines Report (2019) ↗Consensus evidence report

Treatment selection

Typical juvenile-onset myopia generally warrants active control at diagnosis; documented prior progression is not required.

What it supports. Prior change does not reliably identify which child will progress quickly next. Current age and refraction are more useful for estimating remaining risk and likely benefit.

Limits. Find the cause of atypical myopia before applying standard trial results. Several stable years in an older teen or low myopia for age may support observation, but neither proves that future progression is impossible.

SourcesJuvenile-onset myopia—who to treat and how to evaluate success (2024) ↗Clinical evidence reviewIMI Clinical Management Guidelines Report (2019) ↗Consensus evidence report

Treatment selection

Choose a treatment that has evidence, is safe for the child, and can be used correctly and consistently.

What it supports. Several optical and drug treatments work, but their measured effects differ across studies and cannot always be compared directly.

Limits. A trial average does not predict one child’s response. Results depend on the exact product or concentration, population, treatment duration, and outcome measured.

SourcesIMI Interventions for Controlling Myopia Onset and Progression (2025) ↗Evidence reviewCochrane Living Systematic Review of Myopia Control (2025) ↗Living systematic review

Treatment selection

Atropine efficacy is concentration-specific: 0.05% has the strongest evidence among commonly studied low concentrations, 0.025% is intermediate, and 0.01% has shown minimal or no effect in placebo-controlled trials.

What it supports. At two years, LAMP reported SER progression and axial elongation of 0.55 D/0.39 mm with 0.05%, 0.85 D/0.50 mm with 0.025%, and 1.12 D/0.59 mm with 0.01%. A US PEDIG trial found no benefit of 0.01% versus placebo for SER (−0.02 D difference) or axial length (−0.002 mm difference) at two years.

Limits. LAMP enrolled children in Hong Kong; PEDIG enrolled US children. Population, formulation, actual drop use, side effects, and rebound may change the result. No concentration is automatically best for every child.

SourcesTwo-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression Study (2020) ↗Randomized clinical trialLow-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control (2023) ↗Randomized clinical trial

Treatment selection

Atropine 0.01%, PALs, conventional bifocals, spherical RGPs, outdoor time after onset, undercorrection, and standard single-vision correction should not be relied on as primary myopia-control treatments.

What it supports. PEDIG found no benefit from 0.01% atropine. COMET's PAL effect was 0.20 D and 0.11 mm over three years, mostly in year one. Spherical RGP trials found no axial benefit. Outdoor-time effects in established myopes are small or clinically insignificant. Undercorrection has no benefit and may increase progression.

Limits. This does not negate full optical correction or general health counseling. Executive or prismatic bifocals have supportive results in selected studies; modern myopia-control spectacle and contact-lens designs must be judged by their own protocols rather than grouped with conventional lenses.

SourcesIMI—Interventions for Controlling Myopia Onset and Progression 2025 ↗Evidence reviewLow-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control (2023) ↗Randomized clinical trialA Randomized Trial of Rigid Gas Permeable Contact Lenses to Reduce Progression of Children's Myopia (2003) ↗Randomized clinical trialTime Spent Outdoors as an Intervention for Myopia Prevention and Control in Children (2022) ↗Overview of systematic reviewsUndercorrection of Myopia Enhances Rather Than Inhibits Myopia Progression (2002) ↗Randomized clinical trial

Treatment selection

Use evidence from the exact product, design, concentration, dosing schedule, population, outcome, and treatment duration that were studied.

What it supports. The 2025 IMI intervention review includes randomized controlled trials with concurrent controls and axial-length outcomes for mature interventions and reports efficacy separately by modality. Its combination review finds the most developed randomized evidence for orthokeratology plus 0.01% atropine.

Limits. Studies do not identify one best treatment for every child. Results from one spectacle design, contact-lens design, atropine concentration, or combination may not apply to another.

SourcesIMI Interventions for Controlling Myopia Onset and Progression (2025) ↗Evidence reviewCochrane Living Systematic Review of Myopia Control (2025) ↗Living systematic review

Ongoing management

Treatment follow-up should assess vision, safety, tolerance, adherence, and change measured with comparable methods.

What it supports. IMI guidance includes treatment effect and treatment-specific safety in follow-up. Its instrumentation report stresses using consistent measurement methods and accounting for normal test variation.

Limits. No trial proves one best follow-up interval. This trainer uses four months for especially fast progressors and six months otherwise. At three months, true change may be hard to separate from normal measurement variation. Earlier safety or fitting checks are separate.

SourcesIMI Clinical Management Guidelines Report (2019) ↗Consensus evidence reportIMI Instrumentation for Myopia Management (2025) ↗Consensus evidence report

Ongoing management

Treatment cessation should be individualized and followed by continued monitoring with explicit restart triggers.

What it supports. IMI clinical guidance recommends close monitoring after cessation so renewed progression can prompt treatment reinstitution; the 2025 intervention review reports that rebound evidence varies by modality.

Limits. Evidence does not establish one universal stop age, required number of stable years, or optimal atropine taper. Post-cessation evidence remains limited and treatment-specific.

SourcesIMI Clinical Management Guidelines Report (2019) ↗Consensus evidence reportIMI Interventions for Controlling Myopia Onset and Progression (2025) ↗Evidence review

Evidence registry last reviewed August 20, 2026. Published evidence, product labeling, and trainer-specific decision rules remain distinct.

Important limitation

Training tool, not patient-specific guidance

Scores represent the simulator's documented teaching framework. They do not replace examination, professional judgment, current product instructions, local regulation, or individualized care. The generated characters are fictional and the app should never contain real patient information.